Iodide

Iodide

SCHEMBL961213

COc1cc(N=C(N)SC)ccc1-c1nc(C)no1.I

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.40
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3A P46098 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
NOS3 P29474 4/20 0.38
NOS1 P29475 4/20 0.38
NOS2 P35228 2/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
TP53 P04637 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 3/20 0.38
HSD17B10 Q99714 3/20 0.38
MEN1 O00255 2/20 0.38
HTT P42858 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12918148 0.99 CHEK1 (0.41) CHEK1HTR3EHTR3BHTR3AHTR3D
Iodide SCHEMBL964547 0.83 IMPDH2 (0.43) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL12918145 0.81 IMPDH2 (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL960141 0.75 NPC1 (0.44) CHEK1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL964682 0.73 ACHE (0.53) CHEK1NPC1RAB9ATP53SMN1; SMN2
Iodide SCHEMBL964663 0.73 HTR3E (0.39) HTR3EHTR3BHTR3AHTR3DHTR3C
Iodide SCHEMBL2539386 0.72 HTR3E (0.38) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL12918156 0.71 HTR3E (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL961713 0.71 PSEN1 (0.45) CHEK1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4854918 0.71 CHEK1 (0.48) CHEK1NPC1RAB9ATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379553-B1 BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2013-06-26 EP disclosed
US-8349880-B2 Bicyclic compounds for the reduction of beta-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-08 US disclosed
US-20110015175-A1 Bicyclic Compounds for the Reduction of Beta-Amyloid Production BRISTOL-MYERS SQUIBB COMPANY 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015175-A1 Bicyclic Compounds for the Reduction of Beta-Amyloid Production APP, BACE1, APBA1 CHEK1 4705/4885HTR3E 3947/4885HTR3B 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.